SCHEMBL3014642

SCHEMBL3014642

O=S(=O)(c1ccccc1Br)C1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.43
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
DCTPP1 Q9H773 1/20 0.36
HTR2A P28223 3/20 0.36
DNM1L O00429 1/20 0.35
KCNH2 Q12809 2/20 0.35
HTR2C P28335 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
RORC P51449 1/20 0.34
HRH4 Q9H3N8 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008986 0.92 CTSS (0.41) CTSSMEN1KMT2ALMNAMAPK1
SCHEMBL3000401 0.92 CTSS (0.41) CTSSMEN1KMT2ALMNAMAPK1
SCHEMBL3009836 0.92 CTSS (0.41) CTSSMEN1KMT2ALMNAMAPK1
SCHEMBL3014847 0.92 CTSS (0.41) CTSSMEN1KMT2ALMNAMAPK1
SCHEMBL3009993 0.90 CTSS (0.40) CTSSMEN1KMT2ALMNAMAPK1
SCHEMBL3013730 0.90 CTSS (0.41) CTSSMEN1KMT2ALMNAMAPK1
SCHEMBL3015110 0.90 L3MBTL1 (0.43) CTSSLMNAMAPK1NPC1RAB9A
SCHEMBL3011280 0.90 CTSS (0.39) CTSSMEN1KMT2ALMNAMAPK1
SCHEMBL3023029 0.89 CTSS (0.40) CTSSMEN1KMT2ALMNAMAPK1
SCHEMBL3006226 0.89 CTSS (0.40) CTSSMEN1KMT2ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.